Patented biomarker for cardiac injury. 

Patented biomarker for cardiac injury. 

Category: Media & Blogs

It is the first time that a new biomarker showed a higher diagnostic performance than the state-of-the-art for the early diagnosis of Myocardial Infarction.
Webinar held by the ESC 27th of October 2021. ACVC Biomarker Talk Series - A new diagnostic marker on the horizon - cMyC
Cardiac myosin binding protein-C (cMyBP-C) is a critical regulator of heart muscle contraction.
King's College London researchers are developing a point-of-care blood test to diagnose heart attacks that uses cardiac myosin-binding protein C as an alternative biomarker to high-sensitivity troponin used in laboratory testing.
In summary, this is really great work. It’s not quite the 15 minute wonder test that the Daily Mail has suggested, but it does have a lot of promise. We’ll look forward to seeing how this progresses.
The cMyC test correctly excluded a heart attack in 32 per cent of patients. It could mean thousands of patients are given the all-clear and sent home within quarter of an hour of arriving at A&E. Resulting in cost savings for healthcare.
Switching to cMyC from hs-cTn at King's College London, would yearly save the hospital £800,000 through reduced admissions.
Research related to heart attacks shows that the cMyC test has the potential to reassure many thousands more patients with a single test, freeing up valuable hospital beds in ED / A&E.